Companies › Triumvira Immunologics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TAC01-CLDN18.2 anti-CLDN18.2 T-cell Antigen Coupler (TAC) engineered autologous T cell therapy | – | Phase 1 | Metastatic Solid Tumor | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05862324 | TAC01-CLDN18.2 | Phase 1 | Metastatic Solid Tumor | Oncology | Aug 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.